OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.

Attachments



EN
20/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Person Discharging M...

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Attachments

16h / 23m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purchase of ordinary shares by a member of the Company´s Board of Direcors. Attachments

March 14, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Co...

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis) and precision medicine (Licaminlimab, OCS-02, in dry eye disease) treatmentsRecent positive topline results in the ACUITY Phase 2 trial showed Privosegtor (OCS-05)’s neuroprotective benefits in anatomical preservation of the retina and visual function improvements in...

March 11, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Co...

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis) and precision medicine (Licaminlimab, OCS-02, in dry eye disease) treatmentsRecent positive topline results in the ACUITY Phase 2 trial showed Privosegtor (OCS-05)’s neuroprotective benefits in anatomical preserv...

March 11, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins ZUG, Sviss, March 11, 2025 (GLOBE NEWSWIRE) -- Árið 2024 var árangursríkt og einkenndist af verulegum áföngum þróunarlyfja Oculis á síðari stigum klínískra prófana fyrir meðferð á sjúkdómum í sjónhimnu (OCS-01 við sjónhimnubjúg í sykursýki), augntaugasjúkdómum (Privosegtor, OCS-05, við sjóntaugabólgu) og fyrir nákvæmnislyfjameðferð (Licaminlimab, OCS-02, við augnþurrki)Nýlegar jákvæðar niðurstöður (e. topline results) úr fasa 2 ACUITY rannsókninni sýndu fram á taugaverndandi ávinning af notkun...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch